Tacrolimus as Single-Agent Immunotherapy and Minimal Manifestation Status in Nonthymoma Myasthenia Gravis
Background. Tacrolimus is a second-line immunosuppressant in myasthenia gravis (MG) therapy, which is mainly used in combination with corticosteroids to reduce steroid dose and maintain the effect of immunotherapy. However, few studies have focused on the effect of tacrolimus as single-agent immunot...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Hindawi Limited
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/aa5b1f6e27a34ef0bf8a611a9951e7a0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|